Aslan Pharmaceuticals Ltd ADR
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $2.02
- Today's High:
- $2.1
- Open Price:
- $2.08
- 52W Low:
- $1.7025
- 52W High:
- $4.945
- Prev. Close:
- $2.1
- Volume:
- 2417
Company Statistics
- Market Cap.:
- $67.84 million
- Book Value:
- 0.667
- Revenue TTM:
- $189710
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $79.82 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -44.72%
- Return on Equity TTM:
- -209.43%
Company Profile
Aslan Pharmaceuticals Ltd ADR had its IPO on 2018-05-04 under the ticker symbol ASLN.
The company operates in the Healthcare sector and Biotechnology industry. Aslan Pharmaceuticals Ltd ADR has a staff strength of 34 employees.
Stock update
Shares of Aslan Pharmaceuticals Ltd ADR opened at $2.08 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2.02 - $2.1, and closed at $2.02.
This is a -3.81% slip from the previous day's closing price.
A total volume of 2,417 shares were traded at the close of the day’s session.
In the last one week, shares of Aslan Pharmaceuticals Ltd ADR have slipped by -4.36%.
Aslan Pharmaceuticals Ltd ADR's Key Ratios
Aslan Pharmaceuticals Ltd ADR has a market cap of $67.84 million, indicating a price to book ratio of 1.5836 and a price to sales ratio of 19.0541.
In the last 12-months Aslan Pharmaceuticals Ltd ADR’s revenue was $189710 with a gross profit of $79.82 million and an EBITDA of $-54072000. The EBITDA ratio measures Aslan Pharmaceuticals Ltd ADR's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Aslan Pharmaceuticals Ltd ADR’s operating margin was 0% while its return on assets stood at -44.72% with a return of equity of -209.43%.
In Q1, Aslan Pharmaceuticals Ltd ADR’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Aslan Pharmaceuticals Ltd ADR’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-4.2 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Aslan Pharmaceuticals Ltd ADR’s profitability.
Aslan Pharmaceuticals Ltd ADR stock is trading at a EV to sales ratio of 16.936 and a EV to EBITDA ratio of -0.062. Its price to sales ratio in the trailing 12-months stood at 19.0541.
Aslan Pharmaceuticals Ltd ADR stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $60.32 million
- Total Liabilities
- $23.24 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Aslan Pharmaceuticals Ltd ADR ended 2024 with $60.32 million in total assets and $0 in total liabilities. Its intangible assets were valued at $60.32 million while shareholder equity stood at $9.89 million.
Aslan Pharmaceuticals Ltd ADR ended 2024 with $0 in deferred long-term liabilities, $23.24 million in other current liabilities, 63619540.00 in common stock, $-297499047.00 in retained earnings and $0 in goodwill. Its cash balance stood at $57.50 million and cash and short-term investments were $57.50 million. The company’s total short-term debt was $10,748,940 while long-term debt stood at $27.19 million.
Aslan Pharmaceuticals Ltd ADR’s total current assets stands at $60.11 million while long-term investments were $-2946.00 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $10.02 million and inventory worth $0.
In 2024, Aslan Pharmaceuticals Ltd ADR's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Aslan Pharmaceuticals Ltd ADR paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $2.02
- 52-Week High
- $4.945
- 52-Week Low
- $1.7025
- Analyst Target Price
- $16
Aslan Pharmaceuticals Ltd ADR stock is currently trading at $2.02 per share. It touched a 52-week high of $4.945 and a 52-week low of $4.945. Analysts tracking the stock have a 12-month average target price of $16.
Its 50-day moving average was $2.38 and 200-day moving average was $3.15 The short ratio stood at 10.46 indicating a short percent outstanding of 0%.
Around 7.5% of the company’s stock are held by insiders while 2521.4% are held by institutions.
Frequently Asked Questions About Aslan Pharmaceuticals Ltd ADR
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company’s clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.